Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/18/2025

Managing Nocturnal Hypoglycemia in Patients with Diabetes

Understanding the Clinical Picture

  • The American Diabetes Association suggests that patients with nocturnal hypoglycemia (glucose 60 mg/dL) and excellent daytime control (90-115 mg/dL) may have excessive basal insulin coverage overnight, requiring a reduction in basal insulin dose 1
  • Patients with previously elevated A1C (10.4%) may experience improved glycemic control with a combination of glucose-lowering agents, including basal insulin, prandial insulin, and GLP-1 RA 2

Immediate Action: Reduce Lantus Dose

  • The American College of Endocrinology recommends reducing the Lantus dose by 20% immediately (from 28 units to 22-24 units) in patients with nocturnal hypoglycemia and excellent daytime control 1
  • Reducing the insulin dose by 10-20% is recommended when hypoglycemia occurs without clear cause, according to the American Association of Clinical Endocrinologists 1

Monitoring Protocol

  • The Endocrine Society suggests checking fasting glucose daily for the next week after reducing Lantus, with a target fasting glucose of 80-130 mg/dL 1
  • Reassessing the patient in 2-3 weeks with repeat A1C in 3 months is recommended, as the A1C has likely improved substantially 1

Expected Outcomes

  • Reducing Lantus by 20% is expected to resolve nocturnal hypoglycemia within 2-3 days, maintain daytime glucose control (90-115 mg/dL), and achieve fasting glucose in target range (80-130 mg/dL) without nocturnal hypoglycemia 1

REFERENCES

1

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026